Patents by Inventor Xi He

Xi He has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120115172
    Abstract: The present invention relates to a purified molecules, including antibodies, that bind specifically to murine ?-catenin phosphorylated at amino acid position Serine552 and to orthologs thereof, such as mammalian orthologs, including human orthologs. Methods of making and using such purified molecules are also provided. Kits containing such purified molecules are further provided.
    Type: Application
    Filed: December 15, 2011
    Publication date: May 10, 2012
    Inventors: Xi HE, Tong Yin, Qiang Tian, Weiguo Tao, Leroy Hood, Linheng Li
  • Patent number: 8106166
    Abstract: The present invention relates to a purified molecules, including antibodies, that bind specifically to murine ?-catenin phosphorylated at amino acid position Serine552 and to orthologs thereof, such as mammalian orthologs, including human orthologs. Methods of making and using such purified molecules are also provided. Kits containing such purified molecules are further provided.
    Type: Grant
    Filed: March 17, 2008
    Date of Patent: January 31, 2012
    Assignee: Stowers Institute for Medical Research
    Inventors: Xi He, Tong Yin, Qiang Tian, Weiguo Tao, Leroy Hood, Linheng Li
  • Publication number: 20110231942
    Abstract: This invention relates to Tiki1 and Tiki2 proteins and nucleic acids, cells expressing the same, and methods for identifying compounds that modulate Tiki1/2 activity for use in the treatment of osteoporosis or cellular proliferative disorders.
    Type: Application
    Filed: March 16, 2011
    Publication date: September 22, 2011
    Inventors: Xi He, Chika Yokota, Xinjun Zhang, Bryan MacDonald
  • Publication number: 20100301982
    Abstract: In various embodiments, a high frequency transformer is provided. The high frequency transformer may include a magnetic core; a primary winding; and a plurality of secondary windings; wherein the plurality of secondary windings and the primary winding are arranged separately, and each secondary winding constitutes a parasite current transformer with the primary winding.
    Type: Application
    Filed: May 31, 2010
    Publication date: December 2, 2010
    Applicant: OSRAM Gesellschaft mit beschraenkter Haftung
    Inventors: Luca Bordin, Hui Jia, Xi He Zhuang
  • Publication number: 20080248026
    Abstract: The present invention relates to a purified molecules, including antibodies, that bind specifically to murine ?-catenin phosphorylated at amino acid position Serine552 and to orthologs thereof, such as mammalian orthologs, including human orthologs. Methods of making and using such purified molecules are also provided. Kits containing such purified molecules are further provided.
    Type: Application
    Filed: March 17, 2008
    Publication date: October 9, 2008
    Inventors: Xi He, Tong Yin, Qiang Tian, Weiguo Tao, Leroy Hood, Linheng Li
  • Publication number: 20080160253
    Abstract: An exemplary plastic coated edge structure (10) includes a base sheet (11) and a protective plastic layer (12). A fringe portion of the base sheet defines a plurality of through holes (15). The protective plastic layer coats the fringe portion, and part of the protective plastic layer engages in the through holes. A method for making a plastic coated edge structure includes: providing a base sheet including a fringe portion, the fringe portion defining a plurality of though holes; putting the base sheet into an injection mold; injecting a melted plastic material into the injection mold from a side of the fringe portion to an opposite side of the fringe portion from the through holes to form the protective plastic layer for coating the fringe portion; solidifying the plastic material to form a plastic coated edge structure; and taking the plastic coated edge structure out of the injection mold.
    Type: Application
    Filed: August 27, 2007
    Publication date: July 3, 2008
    Applicants: HONG FU JIN PRECISION INDUSTRY (ShenZhen) CO., LTD, HON HAI PRECISION INDUSTRY CO., LTD.
    Inventors: WEN-QUAN LIU, WEI-JIE FAN, XI HE, LIAO-HUA FU
  • Publication number: 20070279906
    Abstract: A LED lighting arrangement includes a support body having mounted thereon one or more LED lighting sources and a driver or feeding the LED lighting sources. The support body includes a high-voltage section carrying the driver and a low-voltage section carrying, mounted on a heat sink, the light sources. An insulation barrier is provided between the high voltage section and the low-voltage section of the board with a twisted pair forming a wiring that traverses the insulation barrier to connect the driver and the LED lighting sources.
    Type: Application
    Filed: May 30, 2007
    Publication date: December 6, 2007
    Applicant: PATENT-TREUHAND-GESELLSCHAFT FUR ELEKTRISCHE GLUHLAMPEN MBH
    Inventors: Xi He, Rui Ma, Giovanni Scilla
  • Patent number: 7183377
    Abstract: The invention provides a novel, secreted protein that contains a region homologous to ligand binding domain of a cytokine receptor. This protein, called Frizzled-related protein (FRP), antagonizes the signaling of the Wnt family of cytokines. Extracellular signaling molecules such as the Wnt family members have essential roles as inducers of cellular proliferation, migration, differentiation, and tissue morphogenesis. As Wnt molecules are known to participate in the aberrant growth associated with neoplasia, Wnt antagonists such as FRP are valuable tools which both for understanding oncogenesis and for the design of new cancer therapies.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: February 27, 2007
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jeffrey S. Rubin, Paul Finch, Stuart Aaronson, Xi He
  • Publication number: 20070036769
    Abstract: The present invention relates to mutant BMP intestinal stem cells (ISCs), with these mutant ISCs possessing an inactive Bmpr1a receptor in which BMP binding is substantially inhibited. The present invention relates to vectors which comprise mutant Bmpr1a nucleic acid sequences, whereby the vectors can be used to promote an increase in the number of ISCs in vivo or in vitro.
    Type: Application
    Filed: June 3, 2004
    Publication date: February 15, 2007
    Inventors: Linheng Li, Xi He
  • Publication number: 20060115815
    Abstract: Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.
    Type: Application
    Filed: April 25, 2003
    Publication date: June 1, 2006
    Inventors: Gabriel Birkus, James Chen, Xiaowu Chen, Tomas Cihlar, Eugene Eisenberg, Marcos Hatada, Gong-Xi He, Choung Kim, William Lee, Martin McDermott, Sundaramoorthi Swaminathan
  • Publication number: 20050271638
    Abstract: The present invention relates to mutant BMP intestinal stem cells (ISCs), with these mutant ISCs possessing an inactive Bmpr1a receptor in which BMP binding is substantially inhibited. The present invention relates to vectors which comprise mutant Bmpr1a nucleic acid sequences, whereby the vectors can be used to promote an increase in the number of ISCs in vivo or in vitro.
    Type: Application
    Filed: June 3, 2004
    Publication date: December 8, 2005
    Inventors: Linheng Li, Xi He
  • Publication number: 20040018150
    Abstract: A novel method is provided for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. Also provided is an improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds for use herein.
    Type: Application
    Filed: January 14, 2003
    Publication date: January 29, 2004
    Inventors: Mark W. Becker, Harlan H. Chapman, Tomas Cihlar, Eugene J. Eisenberg, Gong-Xi He, Michael R. Kernan, William A. Lee, Ernest J. Prisbe, John C. Rohloff, Mark L. Sparacino
  • Publication number: 20030175864
    Abstract: The invention provides a novel, secreted protein that contains a region homologous to ligand binding domain of a cytokine receptor. This protein, called Frizzled-related protein (FRP), antagonizes the signaling of the Wnt family of cytokines. Extracellular signaling molecules such as the Wnt family members have essential roles as inducers of cellular proliferation, migration, differentiation, and tissue morphogenesis. As Wnt molecules are known to participate in the aberrant growth associated with neoplasia, Wnt antagonists such as FRP are valuable tools which both for understanding oncogenesis and for the design of new cancer therapies.
    Type: Application
    Filed: May 3, 2002
    Publication date: September 18, 2003
    Applicant: Secretary, Department of Health and Human Services
    Inventors: Jeffrey S. Rubin, Paul Finch, Stuart Aaronson, Xi He
  • Patent number: 6479255
    Abstract: The invention provides a novel, secreted protein that contains a region homologous to ligand binding domain of a cytokine receptor. This protein, called Frizzled-related protein (FRP), antagonizes the signaling of the Wnt family of cytokines. Extracellular signaling molecules such as the Wnt family members have essential roles as inducers of cellular proliferation, migration, differentiation, and tissue morphogenesis. As Wnt molecules are known to participate in the aberrant growth associated with neoplasia, Wnt antagonists such as FRP are valuable tools which both for understanding oncogenesis and for the design of new cancer therapies.
    Type: Grant
    Filed: May 29, 1998
    Date of Patent: November 12, 2002
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Jeffrey S. Rubin, Paul Finch, Stuart Aaronson, Xi He